Immunitybio Inc (IBRX) — Technical state
As of 2026-11-03 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.
The Closelooknet read
- Closelooknet score: 38 out of 100 (momentum 68 · quality 24 · valuation 6), as of 2026-11-04.
- Signal: Pullback inside an uptrend stack — Trades -5% vs the 50-day and +4.5% vs the 200-day average, 33.3% below the 52-week high and +325.1% off the 52-week low. Computed from daily closes. (as of 2026-11-03)
- Trend: Immunitybio Inc trades 5.0% below its 50-day and 4.5% above its 200-day moving average. (as of 2026-11-03)
ImmunityBio is a biotechnology company that designs immunotherapies meant to activate the immune system against cancer and infectious disease. It develops several platforms, including engineered cytokine proteins, DNA-based vectors and cell therapies, aimed at solid and liquid tumours.
The full read — the desk's view, the earnings record, peers and the company snapshot — is on the IBRX overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.
Trades -5% vs the 50-day and +4.5% vs the 200-day average, 33.3% below the 52-week high and +325.1% off the 52-week low. Computed from daily closes.
The moving-average stack
- vs 20-day-7.9%
- vs 50-day-5%
- vs 200-day+4.5%
- 52-week band33.3% off the high · +325.1% off the low
- Streak1 consecutive up session
- 50-day crossprice crossed down through the 50-day 2 sessions ago
- Stochastic%K 19.6 · %D 20.5
Continue: the IBRX chart & overview · quality & forensics · the earnings record · the signal board
FAQ · from the current data · as of 2026-11-03
Quick answers
What is the current Closelooknet signal on IBRX?
Pullback inside an uptrend stack — Trades -5% vs the 50-day and +4.5% vs the 200-day average, 33.3% below the 52-week high and +325.1% off the 52-week low. Computed from daily closes. As of 2026-11-03; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.
Is IBRX above its 50-day and 200-day moving averages?
As of 2026-11-03, Immunitybio Inc trades -5% below its 50-day and +4.5% above its 200-day average, with the 20-day -7.9% away.
How far is IBRX from its 52-week high?
33.3% below the 52-week high and 325.1% above the 52-week low, as of 2026-11-03.
Related in the Closelooknet universe
then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- HALO Halozyme Therapeutics Incindustry
- ARGX.BR Argen-Xindustry
- ONC BeOne Medicines AGindustry
- UCB.BR UCB SAindustry
- ARGX argenx NV ADRindustry
- REGN Regeneron Pharmaceuticals Incindustry
- REPL Replimune Group Incindustry
- KOD Kodiak Sciences Incindustry
- MRNA Moderna Incindustry
- EXEL Exelixis Incindustry
- ARQT Arcutis Biotherapeutics Incindustry
- XNCR Xencor Incindustry
- MAZE Maze Therapeutics, Inc. Common Stockindustry
- VRDN Viridian Therapeutics Incindustry
- ALK-B.CO ALK-Abelló A/Sindustry
- BHVN Biohaven Ltd.industry
- IRON Disc Medicine Inc.industry
- MEDCL.PA Medincell SAindustry
- ORKA Oruka Therapeutics, Inc.industry
- ONT.L Oxford Nanopore Technologies Ltdindustry